絞り込み

16532

広告

Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population.

著者 Willey V , Franchino-Elder J , Fu AC , Wang C , Sander S , Tan H , Kraft E , Jain R
BMJ Open.2018 Jun 30 ; 8(6):e020676.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (16view , 0users)

Full Text Sources

With the approval of new non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation (NVAF), it is anticipated that their introduction may change NVAF treatment patterns; however, there is limited supporting real-world evidence. This study investigated guideline-recommended oral anticoagulation (OAC) treatment and persistence in newly diagnosed patients with NVAF to understand demographic and clinical characteristics.
PMID: 29961012 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード